BACKGROUND: Accumulating evidence suggests that Ginkgo biloba is cardioprotective, in part, through its vasodilatory and antihypertensive properties. However, definitive data on its blood pressure (BP)-lowering effects in humans is lacking. METHODS: We determined the effects of G. biloba extract (240 mg/day) on BP and incident hypertension in 3,069 participants (mean age, 79 years; 46% female; 96% white) from the Ginkgo Evaluation of Memory (GEM) study. We also examined whether the treatment effects are modified by baseline hypertension status. RESULTS: At baseline, 54% of the study participants were hypertensive, 28% were prehypertensive, and 17% were normotensive. Over a median follow-up of 6.1 years, there were similar changes in BP and pulse pressure (PP) in the G. biloba and placebo groups. Although baseline hypertension status did not modify the antihypertensive effects of G. biloba, it did influence the changes in BP variables observed during follow-up, with decreases in hypertensives, increases in normotensives, and no changes in prehypertensives. Among participants who were not on antihypertensive medications at baseline, there was no difference between treatment groups in medication use over time, as the odds ratio (95% confidence interval (CI)) for being a never-user in the G. biloba group was 0.75 (0.48-1.16). The rate of incident hypertension also did not differ between participants assigned to G. biloba vs. placebo (hazard ratio (HR), 0.99, 95% CI, 0.84-1.15). CONCLUSIONS: Our data indicate that G. biloba does not reduce BP or the incidence of hypertension in elderly men and women.
RCT Entities:
BACKGROUND: Accumulating evidence suggests that Ginkgo biloba is cardioprotective, in part, through its vasodilatory and antihypertensive properties. However, definitive data on its blood pressure (BP)-lowering effects in humans is lacking. METHODS: We determined the effects of G. biloba extract (240 mg/day) on BP and incident hypertension in 3,069 participants (mean age, 79 years; 46% female; 96% white) from the Ginkgo Evaluation of Memory (GEM) study. We also examined whether the treatment effects are modified by baseline hypertension status. RESULTS: At baseline, 54% of the study participants were hypertensive, 28% were prehypertensive, and 17% were normotensive. Over a median follow-up of 6.1 years, there were similar changes in BP and pulse pressure (PP) in the G. biloba and placebo groups. Although baseline hypertension status did not modify the antihypertensive effects of G. biloba, it did influence the changes in BP variables observed during follow-up, with decreases in hypertensives, increases in normotensives, and no changes in prehypertensives. Among participants who were not on antihypertensive medications at baseline, there was no difference between treatment groups in medication use over time, as the odds ratio (95% confidence interval (CI)) for being a never-user in the G. biloba group was 0.75 (0.48-1.16). The rate of incident hypertension also did not differ between participants assigned to G. biloba vs. placebo (hazard ratio (HR), 0.99, 95% CI, 0.84-1.15). CONCLUSIONS: Our data indicate that G. biloba does not reduce BP or the incidence of hypertension in elderly men and women.
Authors: K Umegaki; K Shinozuka; K Watarai; H Takenaka; M Yoshimura; P Daohua; T Esashi Journal: Clin Exp Pharmacol Physiol Date: 2000-04 Impact factor: 2.557
Authors: Richard L Nahin; Monica Pecha; Diana B Welmerink; Kaycee Sink; Steven T DeKosky; Annette L Fitzpatrick Journal: J Am Geriatr Soc Date: 2009-06-08 Impact factor: 5.562
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: James S Kalus; Alexandria A Piotrowski; Christopher R Fortier; Xinhcun Liu; Jeffrey Kluger; C Michael White Journal: Ann Pharmacother Date: 2003-03 Impact factor: 3.154
Authors: David E Vance; Pariya L Fazeli; Linda Moneyham; Norman L Keltner; James L Raper Journal: J Assoc Nurses AIDS Care Date: 2013 Jan-Feb Impact factor: 1.354
Authors: Haruhiro Yamashita; Sailesh Surapureddi; Ramesh C Kovi; Sachin Bhusari; Thai Vu Ton; Jian-Liang Li; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; Cynthia V Rider; Mark J Hoenerhoff; Robert C Sills; Arun R Pandiri Journal: Arch Toxicol Date: 2020-04-18 Impact factor: 5.153
Authors: Cynthia V Rider; Abraham Nyska; Michelle C Cora; Grace E Kissling; Cynthia Smith; Gregory S Travlos; Milton R Hejtmancik; Laurene M Fomby; Curtis A Colleton; Michael J Ryan; Linda Kooistra; James P Morrison; Po C Chan Journal: Toxicol Pathol Date: 2013-08-19 Impact factor: 1.902
Authors: Paula Gardiner; Amanda C Filippelli; Ekaterina Sadikova; Laura F White; Brian W Jack Journal: Evid Based Complement Alternat Med Date: 2015-04-12 Impact factor: 2.629
Authors: Carlos Enrique Escárcega-González; Irma Guadalupe Reynoso-Andeola; Fernando Jaramillo-Juárez; Haydée Martínez-Ruvalcaba; Francisco A Posadas Del Rio Journal: Biochem Res Int Date: 2016-03-03